WO2025041076 - BICYCLIC COMPOUNDS AS CDK INHIBITORS
National phase entry is expected:
Publication Number
WO/2025/041076
Publication Date
27.02.2025
International Application No.
PCT/IB2024/058177
International Filing Date
22.08.2024
Title **
[English]
BICYCLIC COMPOUNDS AS CDK INHIBITORS
[French]
COMPOSÉS BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE CDK
Applicants **
BEIGENE SWITZERLAND GMBH
Inventors
HUO, Changxin
ZHAO, Yu
LI, Honglei
LIU, Huaqing
WANG, Zhiwei
Priority Data
PCT/CN2023/114739
24.08.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2318 | |
| EPO | Filing, Examination, Granting | 9333 | |
| Japan | Filing, Examination, Granting | 2122 | |
| South Korea | Filing, Examination, Granting | 2004 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
21,117
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are bicyclic compound derivatives used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.[French]
L'invention concerne des dérivés de composés bicycliques utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines. L'invention concerne l'utilisation de ces inhibiteurs pour inhiber des kinases dépendantes des cyclines, et l'utilisation de tels composés pour le traitement du cancer.